Oxford Biomedica PLC

Director's Dealing • Jun 10, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6144G

Oxford Biomedica PLC

10 June 2013

Oxford BioMedica plc

Director's Share Purchase

Oxford, UK - 10 June 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 7 June 2013 that six of its Directors had acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

				Interest after purchase
Director / PDMR	Title	Price per share (p)	Number of Ordinary Shares acquired on 07 June 2013	Number of Ordinary Shares	% of total issued share capital
Paul Blake	NED	1.750	113,097	533,097	0.037%
John Dawson	CEO	1.750	282,829	2,282,829	0.161%
Andrew Heath	NED	1.789	180,000	500,000	0.035%
Peter Nolan	SVP	1.750	169,675	733,313	0.052%
Nick Rodgers	Chairman	1.750	282,829	634,829	0.045%
Timothy Watts	CFO	1.750	282,829	3,282,829	0.232%

The issued share capital of the Company is 1,416,149,005 1p ordinary shares.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: +44 (0)1865 783 000
Nomura Code Securities Limited: Juliet Thompson/Jonathan Senior/Christopher Golden	Tel: +44 (0)20 7776 1200
Media Enquiries: Mary-Jane Elliott/Sarah Macleod/Claire Dickinson M:Communications	Tel: +44 (0)20 7920 2360

Notes to editors

1. About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSQDLFBXQFLBBE